Generation Bio Co.

    Generation Bio Co.

    NNASDAQ:GBIO
    5.34
    USD
    0.00
    (0.00%)
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    0.02
    - -
    - -
    - -
    - -
    0.92
    2.99
    2.28
    Basic EPS, GAAP
    -18.18
    -19.53
    -29.54
    -21.17
    -23.51
    -19.63
    -19.76
    -9.34
    Free Cash Flow per Basic Share
    -15.81
    -19.22
    -27.76
    -17.37
    -19.14
    -9.33
    -13.65
    -17.11
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -23.93
    -34.55
    -69.33
    -54.73
    -76.53
    -88.61
    -105.52
    -111.01
    Tangible Book Value per Share
    -21.12
    -31.41
    98.33
    67.81
    48.61
    31.5
    12.94
    7.54
    Basic Weighted Avg Shares
    2
    3
    3
    6
    6
    6
    7
    7
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    - -
    6
    20
    15
    Operating Margin (%)
    -103,594.44
    - -
    - -
    - -
    - -
    -2,346.93
    -398.11
    -589.59
    Depreciation Expense
    - -
    2
    3
    5
    5
    5
    5
    5
    Net Income, GAAP
    -36
    -61
    -81
    -119
    -137
    -127
    -132
    -63
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    -99,452.78
    - -
    - -
    - -
    - -
    -2,144.51
    -661.91
    -410.13
    Working Capital
    70
    9
    257
    360
    268
    233
    158
    72
    LT Debt
    - -
    - -
    - -
    76
    75
    90
    81
    20
    Total Equity
    -42
    -99
    268
    382
    282
    203
    86
    51
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Mar'25
    Jun'25
    Sep'25
    ST Debt
    9
    10
    6
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    78
    76
    20
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    7
    7
    7
    Market Capitalization
    27
    21
    41

    Working Capital

    USD

    •

    in mil. unless spec.
    Mar'25
    Jun'25
    Sep'25
    Total Current Assets
    165
    146
    93
    Cash, Cash Equivalents & STI
    158
    141
    90
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    20
    19
    21
    Payables & Accruals
    5
    5
    4
    ST Debt
    9
    10
    6
    Deferred Revenue
    2
    2
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    -88.21%
    -57.56%
    Free Cash Flow
    - -
    14.75%
    51.25%
    Net Income, GAAP
    - -
    18.12%
    3.99%
    Sales/Revenue/Turnover
    - -
    - -
    236.92%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    1
    2
    3
    6
    2024
    4
    4
    8
    4
    20
    2025
    9
    1
    2
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -5.33
    -4.73
    -4.29
    - -
    -19.63
    2024
    -11.22
    -3.07
    -2.29
    -3.2
    -19.76
    2025
    -2.21
    -3.12
    -0.82
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • businesswire.com

      Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide

    • defenseworld.net

      Generation Bio Co. (NASDAQ:GBIO) Receives Average Recommendation of “Hold” from Brokerages

    • defenseworld.net

      Brokerages Set Generation Bio Co. (NASDAQ:GBIO) PT at $9.25

    • prnewswire.com

      Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders

    • businesswire.com

      GBIO Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Generation Bio Co. is Fair to Shareholders

    • globenewswire.com

      XOMA Royalty Enters into Agreement to Acquire Generation Bio

    • globenewswire.com

      Generation Bio Announces Third Quarter 2025 Financial Results

    • defenseworld.net

      Comparing Generation Bio (NASDAQ:GBIO) & Nuvation Bio (NYSE:NUVB)

    • globenewswire.com

      Generation Bio Announces CEO Transition

    • zacks.com

      Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

    • globenewswire.com

      Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results

    • globenewswire.com

      Generation Bio Announces 1-for-10 Reverse Stock Split

    • globenewswire.com

      Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    • https://www.defenseworld.net

      Squarepoint Ops LLC Takes Position in Generation Bio Co. (NASDAQ:GBIO)

    • globenewswire.com

      Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference

    • zacks.com

      Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates

    • globenewswire.com

      Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

    • globenewswire.com

      Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference

    • zacks.com

      Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates

    • globenewswire.com

      Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results